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4561988, statin therapy was available for 43 (30.3%) of all
FH parents before they were 30 years of age. For the
remaining 99 (69.7%) parents, statins could have
been initiated at the earliest after the age of 30 years.
In the group of affected parents, 64 (41.6%) had a
cardiovascular event during follow-up, mostly a
myocardial infarction (n ¼ 43; 67.2%). At the age of
30 years, the cumulative CVD survival in the parental
FH group was near 90% (Figure 1). None of the
mothers had died before the age of 30, whereas
the cumulative incidence of death due to CVD of the
fathers was almost 5%. The youngest parent with a
myocardial infarction was 20 years old and deceased
from the consequences at the age of 23 years.
Our ﬁndings that FH parents experiencing cardio-
vascular events at a younger age than those FH chil-
dren treated from childhood onwards are in line with
the results of Kusters et al. (5). They found in the
same study population that long-term statin treat-
ment initiated during childhood was associated with
normalization of carotid intima–media thickness
(IMT) progression in FH subjects. Furthermore,
earlier initiation of statin therapy was associated with
thinner carotid IMT at follow-up. Because carotid IMT
is an established marker of early atherosclerosis,
these results support the pivotal role of statins in the
inhibition of the development of early atherosclerotic
lesions in FH children.
Altogether, our results suggest that initiation of
statin therapy in childhood may be effective in the
prevention of very premature CVD and cardiovascular
mortality. These ﬁndings underline the importance of
early diagnosis and treatment of FH patients that
should include initiation of statin treatment as well
as modulation of other major CVD risk factors,
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With DiabetesAmong diabetic patients, hemoglobin A1c (HbA1c) is
an important indicator of glycemic control and,
together with blood pressure and cholesterol, is an
indicator for risk of complications, including cardio-
vascular disease (CVD) and mortality. At present,
there is no universal consensus on the optimal HbA1c
level. Despite this, most international guidelines
include a recommended HbA1c target range or level
as a treatment goal. Several studies have identiﬁed
a J-shaped curvilinear relationship between HbA1c
and CVD incidence and all-cause mortality, but
such a relationship has not yet been conﬁrmed in a
Chinese population (1). There are substantial dif-
ferences in disease risks across racial and ethnic
groups due to genetic and environmental factors
including life-style and health behaviors, and thus,
previous results from Western studies may not be
transferable to a Chinese population (2). We sought
to examine the association among mean HbA1c,
CVD events, and mortality among Chinese primary
care patients with type 2 diabetes mellitus (T2DM)
in Hong Kong.
FIGURE 1 Adjusted Hazard Ratios for Incidence of CVD, CHD, Stroke, Heart Failure, All-Cause Mortality, and CVD–Related Mortality
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Blue lines refer to the adjusted hazard ratios of Cox proportional hazard regression. Error bars indicate 95% conﬁdence intervals. CHD ¼ coronary heart disease; CVD ¼
cardiovascular disease; HbA1c ¼ glycosylated hemoglobin.
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457A population-based retrospective cohort study
was conducted on 117,389 Chinese adult T2DM pri-
mary care patients without any CVD history and who
had an HbA1c value recorded between August 1,
2008, and December 31, 2009. Data was extracted
from the computerized administrative database of
Hong Kong Hospital Authority. The date of the ﬁrst
recorded HbA1c was used as the baseline date for
each subject. Each subject was then tracked to
identify: the date of incidence of an outcome event,
the date of all-cause mortality, or until December 31,
2013, whichever came ﬁrst. The study outcomes
included: 1) CVD event with 1 of the following sub-
type diagnoses: coronary heart disease (CHD), stroke,
or heart failure; 2) CHD; 3) stroke; 4) heart failure;
5) all-cause mortality; and 6) CVD-related mortality.
Comorbidities were identiﬁed by the diagnosis coding
system of International Classiﬁcation of Primary Care-
2 and International Classiﬁcation of Diseases, Ninth
Edition, Clinical Modiﬁcation. A “mean HbA1c” valuewas determined by calculating the average of all
HbA1c measurements collected during follow-up.
Baseline covariates included: age; sex; smoking sta-
tus; drinking habit; body mass index; waist-to-hip ra-
tio; systolic and diastolic blood pressure; low-density
lipoprotein cholesterol; total cholesterol to high-
density lipoprotein cholesterol ratio; triglycerides;
urine albumin-to-creatinine ratio; self-reported dura-
tion of diabetes; family history of diabetes; hyperten-
sion; the stage of chronic kidney disease; and baseline
use of antihypertensive drugs, metformin, sulfonyl-
urea, other oral antidiabetic drugs (acarbose, glita-
zone, gliptin, glucagon-like peptide-1 agonist, and
meglitinides), insulin, and lipid-lowering agents.
Missing data (other than HbA1c) were handled
by multiple imputation method. Study subjects were
divided into 10 groups according to their mean
HbA1c measurement (<6.0%, $6.0% to <6.5%, $6.5%
to <7.0%, $7.0% to <7.5%, $7.5% to <8.0%, $8.0% to
<8.5%, $8.5% to <9.0%, $9.0% to <9.5%, $9.5%
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458to <10.0%, and $10.0%). The relationship between
HbA1c group and study outcomes were evaluated
using multivariable Cox Proportional Hazard regres-
sion, adjusting for all baseline covariates. The statis-
tical procedures were repeated using updated HbA1c
as a time-updated analysis.
After a median follow-up of 54.5 to 58.5 months,
amongst the 10 HbA1c groups, unadjusted incidence
rates for CVD events and all-cause mortality were 13.8
to 28.8 and 9.4 to 32.3 per 1,000 person-years,
respectively. A J-shaped curvilinear relationship was
identiﬁed between HbA1c levels and CVD incidence,
all-cause mortality, as well as other outcomes
(Figure 1). An HbA1c range of $7.0% to <7.5% had the
lowest risk of new CVD, CHD, stroke, heart failure, all-
cause mortality, and CVD-related mortality. When
compared to a HbA1c range of $7.0% to <7.5%,
HbA1c <6.5% or $8.0% was associated with a signif-
icantly higher incidence of CVD and all-cause
mortality. Similar results were obtained in the time-
updated analysis.
This study had several limitations. This was a
retrospective cohort study, which is lower in terms of
evidence hierarchy than a randomized controlled
trial. Drug exposure over time and life-style behavior
risk factors such as diet and exercise were not taken
into account in the analyses. This study was under-
taken in Hong Kong, and the pattern of association
between HbA1c and outcomes may differ in other
Chinese populations. The relationship may be subject
to temporal changes and modiﬁcations in unmea-
sured risk factors or interventions.
The results of this territory-wide, naturalistic,
cohort study of Chinese primary care patients with
T2DM supports the ﬁndings of previous observational
studies conducted in the United States, United
Kingdom, Denmark, and the Netherlands, demon-
strating a J-shaped pattern of association between
HbA1c and CVD and all-cause mortality (1). Similar J-
shaped relationships were also identiﬁed for CHD,
stroke, heart failure, and CVD-related mortality.
Although this phenomenon has been postulated to
be related to the deleterious effects of severe hypo-
glycemia (3), this is controversial, and it remains
unclear why low levels of HbA1c are associated with
a higher risk of CVD and all-cause mortality.*Eric Yuk Fai Wan, MSc, CStat
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Acute Coronary SyndromeThe study by Motoyama et al. (1) expands on their
previous excellent sentinel work (2). The authors
showed that in 3,158 patients with a mean follow up
of 3.4  2.4 years, computed tomography angiog-
raphy (CTA)-veriﬁed high-risk plaque (HRP) was an
independent predictor of acute coronary syndrome
(ACS). In addition, in a subgroup of 449 patients
who underwent serial CTA, plaque progression was
an independent predictor of ACS.
The authors deﬁned HRP on the basis of 2 high-risk
features, positive remodeling (remodeling index $1.1)
and low-attenuation plaque (<30 HU). It would have
been of interest whether the addition of other less
sensitive, but more speciﬁc, high-risk features such as
spotty calciﬁcation and napkin ring sign (3) would
have led to better prediction of ACS.
Secondly, the assessment of plaque volume, which
has been the strongest independent predictor of long-
term ACS (4), was not reported in this study. Instead
of deﬁning plaque progression using quantitative
analysis of plaque volume as is standardly done in
serial intravascular ultrasound studies, plaque pro-
gression was deﬁned as either an increase in stenosis
by at least 1 grade or an increase in the remodeling
index in this study. In addition, low-attenuation
